Pfizer and Bain Capital have teamed up to form a new biotech, Cerevel Theracpeutics. The company will focus on development drug candidates to treat disorders of the central nervous system. Prizer is contributing a portfolio of pre-commercial neuroscience assets and Bain Capital is providing #350 million in capital.
Cerevel will start with a pipeline led by PF-06649751, a dopamine 1 partial agonist for Parkinson’s that is due to start a phase 3 study next year and is intended to use remote patient-monitoring technology provided by IBM.
Following after are two phase 2-ready programs, including GABA 2/3 antagonist PF-06372865 for epilepsy and an M4 positive allosteric modulator that Cerevel.
Click here to view the entire article.